Neoadjuvant and adjuvant trials in non-small cell lung cancer

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Adjuvant therapy in non-small cell lung cancer has become a controversial topic during this present decade. Postoperative thoracic irradiation has the potential to decrease local recurrence and lessen the probability of postobstructive pneumonia or atelectasis. However, as a single modality, in several randomized studies, it has failed to have a favorable impact on survival. Most postoperative adjuvant chemotherapy studies, likewise, have not improved survival compared with operation alone. Recently, there has been a resurgence of interest in preoperative (neoadjuvant) chemotherapy in clinical stage IIIA disease, based on two very positive, albeit small, phase III studies. Improved chemotherapy in stage IV disease using newer and more effective agents, such as vinorelbine (Navelbine), paclitaxel (Taxol), or gemcitabine (Gemzar), is now available. It is hoped that the modest gains in stage IV disease can translate to more significant improvement in earlier stage disease.

Original languageEnglish
Pages (from-to)208-211
Number of pages4
JournalAnnals of Thoracic Surgery
Volume65
Issue number1
DOIs
StatePublished - Jan 1998

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Paclitaxel
Drug Therapy
Pulmonary Atelectasis
Adjuvant Chemotherapy
Pneumonia
Thorax
Recurrence
vinorelbine
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Neoadjuvant and adjuvant trials in non-small cell lung cancer. / Einhorn, Lawrence.

In: Annals of Thoracic Surgery, Vol. 65, No. 1, 01.1998, p. 208-211.

Research output: Contribution to journalArticle

@article{91e5bd5130b54f7a99f18214987e8a01,
title = "Neoadjuvant and adjuvant trials in non-small cell lung cancer",
abstract = "Adjuvant therapy in non-small cell lung cancer has become a controversial topic during this present decade. Postoperative thoracic irradiation has the potential to decrease local recurrence and lessen the probability of postobstructive pneumonia or atelectasis. However, as a single modality, in several randomized studies, it has failed to have a favorable impact on survival. Most postoperative adjuvant chemotherapy studies, likewise, have not improved survival compared with operation alone. Recently, there has been a resurgence of interest in preoperative (neoadjuvant) chemotherapy in clinical stage IIIA disease, based on two very positive, albeit small, phase III studies. Improved chemotherapy in stage IV disease using newer and more effective agents, such as vinorelbine (Navelbine), paclitaxel (Taxol), or gemcitabine (Gemzar), is now available. It is hoped that the modest gains in stage IV disease can translate to more significant improvement in earlier stage disease.",
author = "Lawrence Einhorn",
year = "1998",
month = "1",
doi = "10.1016/S0003-4975(97)01150-8",
language = "English",
volume = "65",
pages = "208--211",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Neoadjuvant and adjuvant trials in non-small cell lung cancer

AU - Einhorn, Lawrence

PY - 1998/1

Y1 - 1998/1

N2 - Adjuvant therapy in non-small cell lung cancer has become a controversial topic during this present decade. Postoperative thoracic irradiation has the potential to decrease local recurrence and lessen the probability of postobstructive pneumonia or atelectasis. However, as a single modality, in several randomized studies, it has failed to have a favorable impact on survival. Most postoperative adjuvant chemotherapy studies, likewise, have not improved survival compared with operation alone. Recently, there has been a resurgence of interest in preoperative (neoadjuvant) chemotherapy in clinical stage IIIA disease, based on two very positive, albeit small, phase III studies. Improved chemotherapy in stage IV disease using newer and more effective agents, such as vinorelbine (Navelbine), paclitaxel (Taxol), or gemcitabine (Gemzar), is now available. It is hoped that the modest gains in stage IV disease can translate to more significant improvement in earlier stage disease.

AB - Adjuvant therapy in non-small cell lung cancer has become a controversial topic during this present decade. Postoperative thoracic irradiation has the potential to decrease local recurrence and lessen the probability of postobstructive pneumonia or atelectasis. However, as a single modality, in several randomized studies, it has failed to have a favorable impact on survival. Most postoperative adjuvant chemotherapy studies, likewise, have not improved survival compared with operation alone. Recently, there has been a resurgence of interest in preoperative (neoadjuvant) chemotherapy in clinical stage IIIA disease, based on two very positive, albeit small, phase III studies. Improved chemotherapy in stage IV disease using newer and more effective agents, such as vinorelbine (Navelbine), paclitaxel (Taxol), or gemcitabine (Gemzar), is now available. It is hoped that the modest gains in stage IV disease can translate to more significant improvement in earlier stage disease.

UR - http://www.scopus.com/inward/record.url?scp=0031883132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031883132&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(97)01150-8

DO - 10.1016/S0003-4975(97)01150-8

M3 - Article

VL - 65

SP - 208

EP - 211

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 1

ER -